Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Verastem Oncology
< Previous
1
2
Next >
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
August 08, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
July 29, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
July 23, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
July 23, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
July 12, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
July 01, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
May 24, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer
May 23, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
May 09, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
April 18, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
March 18, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
March 14, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
March 11, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
March 05, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
March 05, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
January 29, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
January 18, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 11, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2024
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
December 18, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
December 13, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
November 13, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 08, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
November 07, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
November 06, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
October 26, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
From
Verastem Oncology
Via
Business Wire
Tickers
VSTM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.